- Home
- WALD vs SAGE Comparison
WALD vs SAGE Comparison
Compare WALD & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- SAGE
- Stock Information
- Founded
- WALD 1988
- SAGE 2010
- Country
- WALD United Kingdom
- SAGE United States
- Employees
- WALD N/A
- SAGE N/A
- Industry
- WALD Package Goods/Cosmetics
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- WALD Consumer Discretionary
- SAGE Health Care
- Exchange
- WALD Nasdaq
- SAGE Nasdaq
- Market Cap
- WALD 404.2M
- SAGE 462.2M
- IPO Year
- WALD 2021
- SAGE 2014
- Fundamental
- Price
- WALD $3.65
- SAGE $5.61
- Analyst Decision
- WALD Strong Buy
- SAGE Hold
- Analyst Count
- WALD 4
- SAGE 19
- Target Price
- WALD $5.95
- SAGE $11.53
- AVG Volume (30 Days)
- WALD 129.3K
- SAGE 1.1M
- Earning Date
- WALD 08-27-2024
- SAGE 02-12-2025
- Dividend Yield
- WALD N/A
- SAGE N/A
- EPS Growth
- WALD N/A
- SAGE N/A
- EPS
- WALD N/A
- SAGE N/A
- Revenue
- WALD $240,382,000.00
- SAGE $106,399,000.00
- Revenue This Year
- WALD $27.44
- SAGE N/A
- Revenue Next Year
- WALD $19.55
- SAGE $122.78
- P/E Ratio
- WALD N/A
- SAGE N/A
- Revenue Growth
- WALD N/A
- SAGE 837.60
- 52 Week Low
- WALD $2.41
- SAGE $4.62
- 52 Week High
- WALD $11.72
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- WALD 54.59
- SAGE 50.27
- Support Level
- WALD $3.50
- SAGE $4.94
- Resistance Level
- WALD $4.18
- SAGE $5.91
- Average True Range (ATR)
- WALD 0.23
- SAGE 0.36
- MACD
- WALD 0.03
- SAGE 0.02
- Stochastic Oscillator
- WALD 51.15
- SAGE 69.07
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It is organized into two reportable segments namely Obagi Skincare and Milk Makeup.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.